<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html>
<html xmlns="http://www.w3.org/1999/xhtml">
<head>
<meta http-equiv="Content-Type" content="text/html; charset=UTF-8">
<title>Breast IHC and DISH</title>
<link rel="stylesheet" type="text/css" href="view.css" media="all">
<script type="text/javascript" src="view.js"></script>
<script>
function updateDescription (frm) 
{
    var Template = ""


if (frm.A01.value !== ""){
	Template += "- Estrogen receptor: " + frm.A01.value + "\n";
};

if (frm.A02.value !== ""){
	Template += "  - Intensity: " + frm.A02.value + "\n";
};

if (frm.A03.value !== ""){
	Template += "  - Positive nuclei(%) : " + frm.A03.value + "\n";
};

if (frm.A04.value !== ""){
	Template += "- Progesterone receptor: " + frm.A04.value + "\n";
}

if (frm.A05.value !== ""){
	Template += "  - Intensity: " + frm.A05.value + "\n";
}

if (frm.A06.value !== ""){
	Template += "  - Positive nuclei(%) : " + frm.A06.value + "\n";
}

if (frm.A07.value !== ""){
	Template += "- HER2/neu oncoprotein IHC: " + frm.A07.value + "\n";
}

if (frm.A08.value !== ""){
	Template += "  - Score : " + frm.A08.value + "\n";
}

if (frm.A25.value !== ""){
	Template += "  - Percentage of Cells with Uniform Intense Staining : " + frm.A25.value + "\n";
}

if (frm.A09.value !== ""){
	Template += "- HER2 DISH : " + frm.A09.value + "\n";
}

if (frm.A10.value !== ""){
	Template += "  - Number of tumor cell counted : " + frm.A10.value + "\n";
}

if (frm.A11.value !== ""){
	Template += "  - Average number of HER2 signals (black) per cell : " + frm.A11.value + "\n";
}

if (frm.A12.value !== ""){
	Template += "  - Average number of CEP17 signals (red) per cell : " + frm.A12.value + "\n";
}

if (frm.A13.value !== ""){
	Template += "  - HER2/CEP17 ratio : " + frm.A13.value + "\n";
}

if (frm.A26.value !== ""){
	Template += "  - Percentage of Cells with Amplified HER2 Signals : " + frm.A26.value + "\n";
}

if (document.getElementById("A14").checked || document.getElementById("A15").checked){
	Template += "  - Other ISH abnormalities: "  + "\n";
}

if (document.getElementById("A14").checked){
	Template += frm.A14.value + "\n";
}

if (document.getElementById("A15").checked){
	Template += frm.A15.value + "\n";
}

if (frm.A16.value !== ""){
	Template += "- Proliferation index Ki67 (%) : "+ frm.A16.value + "\n";
}

if (frm.A20.value !== ""){
	Template += "- PD-L1 : "+ frm.A20.value + "\n";
}

if (frm.A22.value !== ""){
	Template += "  - Positive tumor cells TC% or TPS : "+ frm.A22.value + "\n";
}

if (frm.A23.value !== ""){
	Template += "  - Combined positive score CPS : "+ frm.A23.value + "\n";
}

if (frm.A19.value !== ""){
	Template += "\n" + "- Additional notes: " + "\n" + "  - " + frm.A19.value + "\n";
}

if (frm.A17.value !== ""){
	Template += "\n" + "- Cold ischemia and fixation times : " + frm.A17.value + "\n";
}

if (frm.A18.value !== ""){
	Template += "\n" + "- Fixation time in buffered formalin : " + frm.A18.value + "\n";
}

if (frm.A24.value !== ""){
	Template += "\n" + "- Number of viable tumor cells : " + frm.A24.value + "\n";
}

if (frm.A01.value + frm.A04.value !== ""){
	Template += "\n" + "Formalin-fixed paraffin embedded sections were assessed by IHC technique for ER and PR, using Novocastra ER (clone: 6F11) and Dako PR (clone: PgR636) with the Bond polymer refined detection system.";
}

if (frm.A07.value !== ""){
	Template += "\n" + "Formalin-fixed paraffin embedded sections were assessed by IHC technique for HER2, using Ventana monoclonal HER2/neu (4B5) with Ventana BenchMark ULTRA multimer detection system.";
}

if (frm.A09.value !== ""){
	Template += "\n" + "HER2 Dual ISH was performed on formalin-fixed paraffin embedded section with the Ventana INFORM HER2 Dual ISH DNA Probe Cocktail Assay on an automated system, and was examined by a pathologist under light microscopy."
	+ "\n" + "- Patients with breast cancers that are HER2 IHC 3+ or IHC 2+/ISH amplified may be eligible for several therapies that disrupt HER2 signaling pathways." + "\n" +  "- Invasive breast cancers that test 'HER2-negative' (IHC 0, 1+ or 2+/ISH not-amplified) are more specifically considered ’HER2-negative for protein overexpression/gene amplification’ since non-overexpressed levels of the HER2 protein may be present in these cases." + "\n" + "- Patients with breast cancers that are HER2 IHC 1+ or IHC 2+/ISH not-amplified may be eligible for a treatment that targets non-amplified/non-overexpressed levels of HER2 expression for cytotoxic drug delivery (IHC 0 results do not result in eligibility currently).";
} 

if (frm.A22.value !== ""){
	Template += "\n" + "Formalin-fixed paraffin embedded sections were assessed by IHC technique for PD-L1, using the antibody : " + frm.A21.value + ". " 
	            + frm.A24.value + " viable tumor cells are present.";
}   

frm.holdtext.value = Template;
}


function CopyToClipboard() {
  /* Get the text field */
  var copyText = document.getElementById("holdtext");

  /* Select the text field */
  copyText.select();

  /* Copy the text inside the text field */
  document.execCommand("copy");

  /* Alert the copied text */
  alert("Report copied to clipboard");
}
</script>
<style>
table, th, td {
  border: 1px solid silver;
  border-collapse: collapse;
  padding: 4px;
}
</style>
</head>

<body>
<img id="top" src="top.png" alt="">
	<div id="form_container">
	<div class="form_description">
		<h2>
		<a href=".\cap\Cancer-Protocols-2023-03-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.1.REL_CAPCP.pdf" target="_blank">
		<div class="tooltip">Breast biomarkers testing
		<span class="tooltiptext">click to access further explanations in the original CAP template</span>
		</div>
		</a></h2>
	</div>
	
<form>
<p>
<fieldset style="border-color:#e6e6ff;">
	<legend> <label class="description"> Biomarkers assessments : </label></legend>

<p>
- For ER/PR, use Allred scoring for routine service, until further notice.
</p>
<p>
<table align="center">
<caption> CAP protocol (June-2021 updated):</caption>
<tr>
<td>ER assessment:</td>
<td>NEGATIVE: < 1% </td>
<td>POSITIVE: >10%; "LOW POSITIVE": 1-10% </td>
</tr>
<tr>
<td>PR assessment:</td>
<td>NEGATIVE: < 1% </td>
<td>POSITIVE: >10% </td>
</tr>
</table>
</p>
<p>
- For HER2, see 2018 ASCO guidelines below. <br>
- Do not report "HER2-Low" or "HER2 Ultra-Low" at this moment<br>
- Reference for <a href=".\cap\PATHWAY anti-HER-2_neu (4B5) Rabbit Monoclonal Primary Antibody Interpretation Guide for Breast Cancer.pdf" target="_blank">4B5 antibody</a><br>
- For PD-L1, CPS = Total positive cells / (Positive cells + Negative tumor cells).<br>
</p>
<p>
<table border="1">
<col width="40%">

<tr>
<td rowspan="3" valign="top">
<label class="description">- <a href=".\cap\Cancer-Protocols-2022-06-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.0.REL_CAPCP.pdf#page=9" target="_blank">Estrogen recepter (ER) IHC</a> :</label>
</td>
<td>
	<select class="element select large"  ID="A01">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative, Internal control cells present and stain as expected">Negative, Internal control cells present and stain as expected</option>
		<option value="Negative, Internal control cells absent">Negative, Internal control cells absent</option>
		<option value="Negative, other (specify):">Negative, other (specify):</option>
		<option value="Positive (Allred score >2)">Positive (Allred score >2)</option>
		<option value="Positive (>10% positive nuclei)">Positive (>10% positive nuclei)</option>
		<option value="Low Positive (1-10% positive nuclei)">Low Positive (1-10% positive nuclei)</option>
	</select>
</td>
</tr>
<tr>
<td align="right">
<label>- Intensity :</label>
	<select class="element select medium"  ID="A02">
		<option value=""></option>
		<option value="Negative (0)">Negative (0)</option>
		<option value="Weak staining (1)">Weak staining (1)</option>
		<option value="Moderate staining (2)">Moderate staining (2)</option>
		<option value="Strong staining (3)">Strong staining (3)</option>
	</select>
</td>
</tr>
<tr>
<td align="right">
<label>- Positive nuclei (%) :</label>
	<select class="element select medium"  ID="A03">
		<option value=""></option>
		<option value="None (0)">None    (0)</option>
		<option value="< 1% (1)">< 1%    (1)</option>
		<option value="1-10% (2)">1-10%   (2)</option>
		<option value="11-33% (3)">11-33%  (3)</option>
		<option value="34-65% (4)">34-65%  (4)</option>
		<option value="66-100% (5)">66-100% (5)</option>
</select>
</td>
</tr>

<tr>
<td  rowspan="3" valign="top">
<label class="description">- <a href=".\cap\Cancer-Protocols-2022-06-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.0.REL_CAPCP.pdf#page=9" target="_blank">Progesterone recepter (PR) IHC</a> :</label>
</td>
<td>
	<select class="element select large"  ID="A04">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative, Internal control cells present and stain as expected">Negative, Internal control cells present and stain as expected</option>
		<option value="Negative, Internal control cells absent">Negative, Internal control cells absent</option>
		<option value="Negative, other (specify):">Negative, other (specify):</option>
		<option value="Positive (Allred score >2)">Positive (Allred score >2)</option>
		<option value="Positive (>10% positive nuclei)">Positive (>10% positive nuclei)</option>
	</select>
</td>
</tr>

<tr>
<td align="right">
<label>- Intensity :</label>
	<select class="element select medium"  ID="A05">
		<option value=""></option>
		<option value="Negative (0)">Negative (0)</option>
		<option value="Weak staining (1)">Weak staining (1)</option>
		<option value="Moderate staining (2)">Moderate staining (2)</option>
		<option value="Strong staining (3)">Strong staining (3)</option>
	</select></td>
</tr>

<tr>
<td align="right">
<label>- Positive nuclei (%) :</label>
<select class="element select medium"  ID="A06">
		<option value=""></option>
		<option value="None (0)">None    (0)</option>
		<option value="< 1% (1)">< 1%    (1)</option>
		<option value="1-10% (2)">1-10%   (2)</option>
		<option value="11-33% (3)">11-33%  (3)</option>
		<option value="34-65% (4)">34-65%  (4)</option>
		<option value="66-100% (5)">66-100% (5)</option>
</select>
</td>
</tr>

<tr>
<td>
<label class="description">- <a href=".\cap\Cancer-Protocols-2022-06-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.0.REL_CAPCP.pdf#page=17" target="_blank">Ki67 Proliferation index %</a> :</label>
</td>
<td>
<input type="text" ID="A16" class="element text large" size="40">
</td>
</tr>

<tr>
<td rowspan="3" valign="top">
<label class="description">- <a href=".\cap\Cancer-Protocols-2022-06-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.0.REL_CAPCP.pdf#page=13" target="_blank">HER2/neu oncoprotein IHC</a> :</label>
Do not report "HER2-Low" or "HER2 Ultra-Low" at this moment.
</td>
	<td><select class="element select large"  ID="A07">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative for over-expression">Negative for over-expression</option>
		<option value="Equivocal for over-expression">Equivocal for over-expression</option>
		<option value="Positive for over-expression">Positive for over-expression</option>
		<option value="HER2-low (IHC 1+ or IHC 2+ & DISH-)">HER2-low (IHC 1+ or IHC 2+ & DISH-)</option>
		<option value="HER2-ultra-low (faint/barely perceptible and incomplete staining in <10% of tumor cells without amplification on FISH)">HER2-ultra-low (faint/barely perceptible and incomplete staining in <10% of tumor cells without amplification on FISH)</option>
	</select></td>
</tr>

<tr>
<td align="right">
<label>- Score :</label>
	<select class="element select medium"  ID="A08">
		<option value=""></option>
		<option value="0 (no staining) (i.e. negative)">0 (no staining) (i.e. negative)</option>
		<option value="0 (incomplete faint membrane staining within < or = 10% of invasive tumour cells) (i.e. negative)">0 (incomplete faint membrane staining within < or = 10% of invasive tumour cells) (i.e. negative)</option>
		<option value="1 (incomplete, faint membrane staining within >10% of invasive tumour cells) (i.e. negative)">1 (incomplete, faint membrane staining within >10% of invasive tumour cells) (i.e. negative)</option>
		<option value="2 (incomplete circumferential and/or weak/moderate staining within >10% of invasive tumour cells) (i.e. equivocal)">2 (incomplete circumferential and/or weak/moderate staining within >10% of invasive tumour cells) (i.e. equivocal)</option>
		<option value="3 (circumferential, complete and intense membrane staining within >10% of invasive tumour cells) (i.e. positive)">3 (circumferential, complete and intense membrane staining within >10% of invasive tumour cells) (i.e. positive)</option>
	</select></td>
</tr>

<tr>
<td align="right">
- Cells with Intense Complete Stain (%):
<input type="text" class="element text small" ID="A25" size="3"></td>
</tr>

<tr><td rowspan="7" valign="top">
<label class="description">- <a href=".\cap\Cancer-Protocols-2022-06-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.0.REL_CAPCP.pdf#page=15" target="_blank">HER2/neu oncoprotein DISH</a> :</label>
<a href=".\Biomarker-DISH-calculator.html" target="_blank">HER2 DISH calculator</a>
<!--
<br>
<a href=".\cap\her2_dish.xlsx" target="_blank">DOWNLOAD AN EXCEL FILE</a>
-->
</td>
	<td><select class="element select large"  ID="A09">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative for HER2 amplification">Negative for HER2 amplification</option>
		<option value="Equivocal for HER2 amplification">Equivocal for over-expression</option>
		<option value="Positive for HER2 amplification">Positive for HER2 amplification</option>
	</select></td>
</tr>

<tr><td align="right">
- Number of tumor cells counted :
<input type="text" class="element text small" ID="A10" size="10"></td>
</tr>

<tr><td align="right">
- Average HER2 signals (black) per cell :
<input type="text" class="element text small" ID="A11" size="10"></td>
</tr>

<tr><td align="right">
- Average CEP17 signals (red) per cell :
<input type="text" class="element text small" ID="A12" size="10"></td>
</tr>

<tr><td align="right">
- HER2/CEP17 ratio :
<input type="text" class="element text small" ID="A13" size="10"></td>
</tr>
<tr>
<td align="right">
- Cells with Amplified Signals (%):
<input type="text" class="element text small" ID="A26" size="10"></td>
</tr>

<tr>
<td>- Other ISH abnormalities:<br>
	<input class="element checkbox" type="checkbox" id="A14" value="    - Aneusomy"><label  class="choice">Aneusomy</label>
	<input class="element checkbox" type="checkbox" id="A15" value="    - Heterogeneous signals"><label class="choice">Heterogeneous signals</label>
</td>
</tr>

<tr>	
<td rowspan="4" valign="top">
<label class="description">- <a href=".\cap\Approved-Immune-Checkpoint-Inhibitors-20200605.pdf" target="_blank">PD-L1 assessment</a> :</label>
- for triple negative tumors<br>
<a href=".\Biomarker-PDL1-calculator.html" target="_blank">PD-L1 calculator</a>
</td>
<td>
<select class="element select large"  ID="A20">
	<option value=""></option>
	<option value="Cannot be determined">Cannot be determined</option>
	<option value="Negative (CPS<10)">Negative (CPS<10)</option>
	<option value="Positive (combined positive score CPS > or = 10)">Positive (combined positive score CPS > or = 10)</option>
</select>
</td>
</tr>

<tr>
<td align="right">
<label>- Antibody (anti-CD274) :</label>
	<select class="element select small"  ID="A21">
		<option value=""></option>
		<option value="22C3 (Dako)">22C3 (Dako)</option>
		<option value="28-8 (Dako)">28-8 (Dako)</option>
		<option value="SP263 (Roche)">SP263 (Roche)</option>
		<option value="SP142 (Roche)">SP142 (Roche)</option>
		<option value="E1L3N (Cell Signaling)">E1L3N (Cell Signaling)</option>
		<option value="Other, specify:">Other, specify:</option>
	</select>
</td>
</tr>

<tr>
<td align="right">
<label>- Positive tumor cells (TC% or TPS) :</label>
<input type="text" class="element text small" ID="A22" size="35">
</td>
</tr>

<tr>
<td align="right"><label>- Combined positive score (CPS) :</label>
<input type="text" class="element text small" ID="A23" size="35"></td>
</tr>
</table>
</p>

</fieldset>
</p>

<p align="center">
<a href=".\cap\fmolb-09-834651-g001.jpg" target="_blank"><img src=".\cap\fmolb-09-834651-g001.jpg" alt="HER2 IHC" width="600"></a>
<br>
From <a href="https://doi.org/10.3389/fmolb.2022.834651"  target="_blank">Venetis et al Front. Mol. Biosci. 2022.</a>
</p>

<p>
HER2-low<br>
HER2 IHC 2+ AND HER2 DISH negative<br>
OR<br>
HER2 IHC 1+<br>
Tarantino P et al. 2020<br><br>
</p>

<p>
HER2 Ultra-low<br>
It is immunohistochemically characterized by faint/barely perceptible and incomplete staining in =<10% of tumor cells without amplification on FISH. <br>
</p>

<p>
<fieldset style="border-color:#e6e6ff;">
	<legend> <label class="description"> <a href=".\cap\Cancer-Protocols-2022-06-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.0.REL_CAPCP.pdf#page=8" target="_blank">Analytical details</a> : </label></legend>
<p>
<table border="1">
<col width="40%">
<tr>
<td><label>- Cold ischemia and fixation times :</label></td>
	<td><select class="element select large"  ID="A17">
		<option value=""></option>
		<option value="Meet requirements specified in latest version of the ASCO/CAP guidelines">Meet requirements specified in latest version of the ASCO/CAP guidelines</option>
		<option value="Do not meet requirements specified in latest version of the ASCO/CAP guidelines">Do not meet requirements specified in latest version of the ASCO/CAP guidelines</option>
		<option value="Cannot be determined (explain):">Cannot be determined (explain):</option>
	</select></td>
</tr>

<tr>
<td><label>- Fixation time in buffered formalin :</label></td>
	<td><select class="element select large"  ID="A18">
		<option value=""></option>
		<option value="Optimal fixation (6-72 hours)">Optimal fixation (6-72 hours)</option>
		<option value="Prolonged intervals (> 72 hours)">Prolonged intervals (> 72 hours)</option>
		<option value="Uncertain">Uncertain</option>
	</select></td>
</tr>

<tr>
<td><label>- Number of viable tumor cells :</label></td>
	<td><select class="element select large"  ID="A24">
		<option value=""></option>
		<option value="More than or equal to 50">More than or equal to 50</option>
		<option value="More than or equal to 100">More than or equal to 100</option>
		<option value="Less than 100">Less than 100 </option>
	</select></td>
</tr>
</table>
</p>
</fieldset>
</p>

<p align="center" >
<!--
<iframe width="517" height="550" frameborder="1" scrolling="no" src="https://onedrive.live.com/embed?resid=4E150EF5229D3792%2130207&authkey=%21AFkAjAfw58fM5U4&em=2&wdAllowInteractivity=False&AllowTyping=True&ActiveCell='HER2%20DISH'!C7&Item='HER2%20DISH'!A1%3AH22&wdHideGridlines=True&wdInConfigurator=True"></iframe>
<br>
-->
<a href=".\cap\her2_dish.xlsx" target="_blank">DOWNLOAD THE EXCEL FILE</a>
</p>

<p align="center" >
<!--
<iframe width="517" height="350" frameborder="1" scrolling="no" src="https://onedrive.live.com/embed?resid=4E150EF5229D3792%2186767&authkey=%21ADGiu7lwQ89z-xk&em=2&wdAllowInteractivity=False&AllowTyping=True&ActiveCell='Sheet1'!C4&Item='Sheet1'!A1%3AD12&wdHideGridlines=True&wdDownloadButton=True&wdInConfigurator=True"></iframe>
<br>
-->
<a href=".\cap\PD-L1.xlsx" target="_blank">DOWNLOAD THE EXCEL FILE</a>
</p>

<p>
<fieldset style="border-color:#e6e6ff;">
	<legend> <label class="description"> <a href=".\cap\algorithim-evaluation-her2-Fig3.pdf" target="_blank">Dual probe ISH interpretation </a>: </label></legend>
- Group 1 = HER2/CEP17 ratio > or = 2.0;  > or = 4.0 HER2 signals/cell<br>
- Group 2 = HER2/CEP17 ratio > or = 2.0;  < 4.0 HER2 signals/cell (<a href=".\cap\algorithim-evaluation-her2-Fig4.pdf" target="_blank">ASCO 2018 guideline</a>)<br>
- Group 3 = HER2/CEP17 ratio < 2.0;  > or = 6.0 HER2 signals/cell (<a href=".\cap\algorithim-evaluation-her2-Fig5.pdf" target="_blank">ASCO 2018 guideline</a>)<br>
- Group 4 = HER2/CEP17 ratio < 2.0;  > or = 4.0 and < 6.0 HER2 signals/cell (<a href=".\cap\algorithim-evaluation-her2-Fig6.pdf" target="_blank">ASCO 2018</a>)<br>
- Group 5 = HER2/CEP17 ratio < 2.0;  < 4.0 HER2 signals/cell<br>
<br>

<fieldset style="border-color:#e6e6ff;">
	<legend> Negative :</legend>
- Group 5;<br>
- Group 4 and concurrent IHC 0-1+ or 2+;<br>
- Group 3 and concurrent IHC 0-1+; and <br>
- Group 2 and concurrent IHC 0-1+ or 2+;<br>
<br>
</fieldset>
<fieldset  style="border-color:#e6e6ff;">
	<legend> Positive : </legend>
- Group 1;<br>
- Group 2 and concurrent IHC 3+;<br>  
- Group 3 and concurrent IHC 2+ or 3+; and<br>
- Group 4 and concurrent IHC 3+ <br>	
<br>
</fieldset>
<br>
</fieldset>
</fieldset>
</p>

<!--
<p>
<a href=".\cap\lowHER2.png" target="_blank"><img src=".\cap\lowHER2.png" alt="HER2 IHC" width="600"></a>
<br>
From Roche website<br>
<br>
</p>
-->

<!--
<p>
<fieldset style="border-color:#e6e6ff;">
	<legend> <label class="description"> HER2 gene amplification : </label></legend>

<p>
<table border="1">
<col width="40%">

<tr>
<td rowspan="2" valign="top">
<label class="description">- HER2/neu oncoprotein IHC :</label></td>
	<td><select class="element select large"  ID="A07">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative for over-expression">Negative for over-expression</option>
		<option value="Equivocal for over-expression">Equivocal for over-expression</option>
		<option value="Positive for over-expression">Positive for over-expression</option>
	</select></td>
</tr>

<tr><td align="right">
<label>- Score :</label>
	<select class="element select small"  ID="A08">
		<option value=""></option>
		<option value="0 (no staining or incomplete faint membrane staining within < or = 10% of invasive tumour cells) (i.e. negative)">0 (no staining or incomplete faint membrane staining within < or = 10% of invasive tumour cells) (i.e. negative)</option>
		<option value="1 (incomplete, faint membrane staining within >10% of invasive tumour cells) (i.e. negative)">1 (incomplete, faint membrane staining within >10% of invasive tumour cells) (i.e. negative)</option>
		<option value="2 (incomplete circumferential and/or weak/moderate staining within >10% of invasive tumour cells) (i.e. equivocal)">2 (incomplete circumferential and/or weak/moderate staining within >10% of invasive tumour cells) (i.e. equivocal)</option>
		<option value="3 (circumferential, complete and intense membrane staining within >10% of invasive tumour cells) (i.e. positive)">3 (circumferential, complete and intense membrane staining within >10% of invasive tumour cells) (i.e. positive)</option>
	</select></td>
</tr>

<tr><td rowspan="7" valign="top">
<label class="description">- HER2/neu oncoprotein DISH :</label></td>
	<td><select class="element select large"  ID="A09">
		<option value=""></option>
		<option value="Cannot be determined">Cannot be determined</option>
		<option value="Negative for HER2 amplification">Negative for HER2 amplification</option>
		<option value="Equivocal for HER2 amplification">Equivocal for over-expression</option>
		<option value="Positive for HER2 amplification">Positive for HER2 amplification</option>
	</select></td>
</tr>

<tr><td align="right">
- Number of tumor cells counted :
<input type="text" class="element text small" ID="A10" size="10"></td>
</tr>

<tr><td align="right">
- Average HER2 signals (black) per cell :
<input type="text" class="element text small" ID="A11" size="10"></td>
</tr>

<tr><td align="right">
- Averagen CEP17 signals (red) per cell :
<input type="text" class="element text small" ID="A12" size="10"></td>
</tr>

<tr><td align="right">
- HER2/CEP17 ratio :
<input type="text" class="element text small" ID="A13" size="10"></td>
</tr>

<tr>
<td>- Other ISH abnormalities:<br>
	<input class="element checkbox" type="checkbox" id="A14" value="    - Aneusomy"><label ">Aneusomy</label><br>
	<input class="element checkbox" type="checkbox" id="A15" value="    - Heterogeneous signals"><label>Heterogeneous signals</label><br>
<br>
</td>
</tr>
</table>

</p>

<!--
<p>
<fieldset style="border-color:#e6e6ff;">
	<legend> <label class="description"> Other biomarkers : </label></legend>
<p>
<table border="1">
<col width="40%">
<tr>
<td>
<label class="description">- Ki67 Proliferation index % :</label>
</td>
<td>
<input type="text" ID="A16" class="element text large" size="40">
</td>
<tr>

<tr>	
<td rowspan="4" valign="top">
<label class="description">- PD-L1 assessment :</label>
- for triple negative tumors
</td>
<td>
<select class="element select large"  ID="A20">
	<option value=""></option>
	<option value="Cannot be determined">Cannot be determined</option>
	<option value="Negative (<1% positive cells)">Negative (<1% positive cells)</option>
	<option value="Positive (> or = 1% immune cells positive)">Positive (> or = 1% immune cells positive)</option>
	<option value="Positive (combined positive score CPS > or = 1)">Positive (combined positive score CPS > or = 1)</option>
</select>
</td>
</tr>

<tr>
<td align="right">
<label>- Antibody (anti-CD274) :</label>
	<select class="element select small"  ID="A21">
		<option value=""></option>
		<option value="22C3 (Dako)">22C3 (Dako)</option>
		<option value="28-8 (Dako)">28-8 (Dako)</option>
		<option value="SP263 (Roche)">SP263 (Roche)</option>
		<option value="SP142 (Roche)">SP142 (Roche)</option>
		<option value="E1L3N (Cell Signaling)">E1L3N (Cell Signaling)</option>
		<option value="Other, specify:">Other, specify:</option>
	</select>
</td>
</tr>

<tr>
<td align="right">
<label>- Positive tumor cells (TC% or TPS) :</label>
<input type="text" class="element text small" ID="A22" size="35">
</td>
</tr>

<tr>
<td align="right"><label>- Positive immune cells (IC%) :</label>
<input type="text" class="element text small" ID="A23" size="35"></td>
</tr>

</table>
</p>
</fieldset>
</p>
-->

<p>
<label class="description">- Additional notes :</label>
 <textarea ID="A19" class = "element textarea medium" style="border-color:grey;"></textarea> 
</p>



<br><br>
<input type="button" name="copyform" value="Check your Report" onclick="updateDescription(this.form)"/>
<br>
<TEXTAREA ID="holdtext" name="holdtext" class="textarea large" style="border-color:coral;"></TEXTAREA>

<br><br>
<!-- The button used to copy the text -->
<button onclick="CopyToClipboard()">Copy text to Clipboard</button>

<input type="reset" value="Reset Form" name="reset" style="float: right;">
</form>
<br>
<br>

<div id="footer">
Last upated 14-Aug-2024, based on <a href=".\cap\Cancer-Protocols-2023-03-Update\Breast Protocol Folder\Breast.Bmk_1.5.0.1.REL_CAPCP.pdf" target="_blank"> Breast Biomarkers 1.5.0.1 Mar-2023</a>.<br>
html form was created on <a href="https://www.phpform.org">pForm</a>, <a href="https://www.w3schools.com/">W3 School</a>, <a href="https://stackoverflow.com/">StackOverflow</a>, and <a href="https://icons8.com">Icons8</a>.<br><br>
Anatomical Pathology Division, Queen Mary Hospital, Hong Kong.
</div>
</div>
<img id="bottom" src="bottom.png" alt="">
</body>
</html>

